Transcription profiling by array of human B cell lymphoma cell lines in response to rituximab treatment
Ontology highlight
ABSTRACT: HF-1, Granta-519, SUDHL4,Oci-Ly10 and Oci-Ly3 cell lines, representing different B cell lymphoma subtypes, were induced with rituximab (R) for three hours and analyzed for differentially expressed genes compared to untreated control.
Project description:The experiment was designed to profile the transcriptome of human melanoma cell lines that differ in their delta ex2/3p73 expression. The differential gene expression of SK-Mel-29 stably overexpressing delta ex2/3p73-cDNA (SK-Mel-29.DNp73) was analyzed in comparison to parental cells with integrated empty vector . The DNp73-related gene expression signature was compared to the transcriptome of SK-Mel-103 and SK-Mel-147 cells with high endogenous DNp73 expression.
Project description:A doxycycline-inducible Xist cDNA transgene was introduced into mouse chromosome 17 at approximately 71.24Mb (NCBI Build m36). Insertion of the transgene was heterozygous, so only one copy of chromosome 17 carried the transgene, and the other chromosome 17 was wild-type. Upon doxycycline induction, the transgene is expressed, producing Xist transgene RNA which localises to autosomal material in cis, leading to silencing of genes adjacent to the transgene. Due to the heterozygous nature of transgene insertion and the cis nature of silencing, for any silenced gene, the maximum possible downregulation in expression levels was 50%.<br><br><br><br>To quantify the changes in the levels of gene expression in response to Xist transgene expression, total RNA was extracted from undifferentiated and differentiated ES cells treated with doxycycline. As background control, total RNA was also prepared from uninduced cells (both undifferentiated and differentiated, cultured in parallel to doxycycline-treated cells). The total RNA was then used to make labelled cRNA, which was hybridised to an Affymetrix GeneChip Mouse Genome 430 2.0 array.
Project description:A doxycycline-inducible Xist cDNA transgene was introduced into mouse chromosome 3 at approximately 99.79Mb (NCBI Build m36). Insertion of the transgene was homozygous, so only one copy of chromosome 3 carried the transgene, and the other chromosome 3 was wild-type. Upon doxycycline induction, the transgene is expressed, producing Xist transgene RNA which localises to autosomal material in cis, leading to silencing of genes adjacent to the transgene. Due to the homozygous nature of transgene insertion and the cis nature of silencing, for any silenced gene, the maximum possible downregulation in expression levels was 50%.<br><br><br><br>To quantify the changes in the levels of gene expression in response to Xist transgene expression, total RNA was extracted from undifferentiated and differentiated ES cells treated with doxycycline for three days. As background control, total RNA was also extracted from uninduced cells (both undifferentiated and differentiated, cultured in parallel to doxycycline-treated cells). cRNA was labelled from the total RNAs, and then hybridised to Affymetrix GeneChip Mouse Genome 430 2.0 arrays.
Project description:The FSH microarray was performed to identify new genes to be regulated by FSH in granulosa cells, in order to ultimately find genes potentially important in oocyte maturation and development.
Project description:The effect for cell differentiation of phosphorylation of TIF1beta (S824) on the regulation of pluripotency in mouse ES cells was then evaluated. Single amino acid mutagenesis was performed from serine 824 to aspartic acid (SD) or alanine (SA) to mimic phosphorylated or non-phosphorylated versions of TIF1beta, respectively.
Project description:SNP array profile of cell lines from solid tumors showing MYCN amplification as Double minutes (dmin) and homogeneously staining regions (hsr)
Project description:The purpose of the study was to identify downstream gene targets regulated by a new alternative splice of BAFF (B-Cell Activating factor belonging to the TNF Family) that we called Delta4-BAFF (because it characterized by an alternative splice of exon 4). To do this we used human burkitt's lymphoma cell line (RAMOS) stably transfected with Delta4-BAFF or stably transfected with Delta4-BAFF mutated on its N-glycosylation site (Delta4-BAFF-N124D). One control was used : RAMOS stably transfected with empty vector (pIRES2-GFP from Clontech)
Project description:The transcriptional response of BeWo cells stimulated with C. burnetii was analyzed using microarrays covering the whole human genome.
Project description:Comparison of osteoclastic differentiation pathway from DCs with the canonical differentiation pathway from monocytes by transcriptomic profiling